| Ms Grace Doh, | |
|
1831 Forest Dr Ste A, Annapolis, MD 21401-4430 | |
| (410) 268-9400 | |
| (443) 279-0537 |
| Full Name | Ms Grace Doh |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Psychiatric/mental Health |
| Location | 1831 Forest Dr Ste A, Annapolis, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255994802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0808X | Nurse Practitioner - Psychiatric/mental Health | R187663 (Maryland) | Primary |
| Entity Name | Psych Associates Of Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891721981 PECOS PAC ID: 3971550963 Enrollment ID: O20050401000288 |
News Archive
A study published in this month's issue of the Journal of Cataract and Refractive Surgery suggests that rigid contact lens users should stop using contacts and switch to glasses 3 to 6 weeks before having pre-LASIK examinations, rather than the traditional 3 weeks.
Synthelis, a company specializing in the production and characterization of therapeutic targets and antigens, announces today that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.
Approximately 1.5 million children and adults in the U.S. have autism and it is estimated to be the fastest growing developmental disability with a 10 - 17 percent increase each year.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
With skyrocketing Medicare costs contributing to record-setting budget deficits, does the United States need to ration costly end-of-life care? This compelling topic will be the focus of an upcoming debate produced by the Miller Center of Public Affairs at the University of Virginia, in partnership with MacNeil/Lehrer Productions and The National Press Club.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Grace Doh, 120 Sister Pierre Dr Ste 403, Towson, MD 21204-7536 Ph: (410) 823-6408 | Ms Grace Doh, 1831 Forest Dr Ste A, Annapolis, MD 21401-4430 Ph: (410) 268-9400 |
News Archive
A study published in this month's issue of the Journal of Cataract and Refractive Surgery suggests that rigid contact lens users should stop using contacts and switch to glasses 3 to 6 weeks before having pre-LASIK examinations, rather than the traditional 3 weeks.
Synthelis, a company specializing in the production and characterization of therapeutic targets and antigens, announces today that it has secured initial backing of EUR 610,000 from a group of French investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.
Approximately 1.5 million children and adults in the U.S. have autism and it is estimated to be the fastest growing developmental disability with a 10 - 17 percent increase each year.
Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.
With skyrocketing Medicare costs contributing to record-setting budget deficits, does the United States need to ration costly end-of-life care? This compelling topic will be the focus of an upcoming debate produced by the Miller Center of Public Affairs at the University of Virginia, in partnership with MacNeil/Lehrer Productions and The National Press Club.
› Verified 8 days ago
Brenda Kay Mathews-vitello, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 116 Defense Hwy, Suite 400, Annapolis, MD 21401 Phone: 410-897-9841 Fax: 410-897-9852 | |
Mrs. Jillian Lynn Preston, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 166 Defense Hwy Ste 101, Annapolis, MD 21401 Phone: 877-461-1564 | |
Alexa Lee St Laurent, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2024 West St Ste 400, Annapolis, MD 21401 Phone: 410-224-7667 Fax: 410-224-7007 | |
Dabney Lipscomb, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2003 Medical Pkwy, Wayson Pavilion, Suite 150, Annapolis, MD 21401 Phone: 443-481-1199 Fax: 443-481-1495 | |
Ms. Stephanie Zwonitzer, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2001 Medical Pkwy, Annapolis, MD 21401 Phone: 443-481-1750 | |
Mrs. Hollis Stewart Johnson, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 678 Genessee St, Annapolis, MD 21401 Phone: 412-508-7896 | |
Lisa Kristine Butler, MSN, CRNP, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2002 Medical Pkwy Ste 670, Annapolis, MD 21401 Phone: 443-481-1150 |